Our findings suggest that IL-33 may serve as a plausible candidate for predicting 5-FU chemosensitivity and favorable prognoses, as well as a promising adjuvant to generate effective T cell-mediated protective immunity against cancer. This evidence concerns the gene IL33 and cancer.